Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shexiang Baoxin Pills for chronic stable coronary artery disease
ChiCTR-TRC-12003513Phase 4Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Shexiang Baoxin Pill in coronary arteriosclerosis (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Cardiovascular death, Nonfatal myocardial infarction and 1 more. Started Jul 2011; status: completed.
02
Drugs
Shexiang Baoxin Pill
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR-TRC-12003513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12003513.